Positioning of rifampicin in the biopharmaceutics classification system (BCS)

Clinical Research and Regulatory Affairs

Volumn 23, Issue 1, 2006, Pages 1-10

  Mariappan, T T ^a   Singh, Saranjit ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Biopharmaceutics classification system; FDA; Permeability; Rifampicin; Solubility

Indexed keywords

CAFFEINE; FUROSEMIDE; NAPROXEN; RANITIDINE; RIFAMPICIN;

ANIMAL TISSUE; ARTICLE; CELL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG PENETRATION; DRUG SOLUBILITY; DUODENUM; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ILEUM; INTESTINE; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; NONHUMAN; RAT;

EID: 33645579899     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1080/10601330500533990     Document Type: Article

References (34)

1. Frick A, Moller H, Wirbitzki E. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethyl penicillin potassium, glimepride and levofloxacin. Eur J Pharm Biopharm 1998; 46: 305-311.
2. Lentz KA, Hayashi J, Lucisano LJ, Polli JE. Development of a more rapid reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. Int J Pharm 2000; 200: 41-51.
3. Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 2002; 91: 719-729.
4. Alt A, Potthast H, Moessinger J, Sickmuller B, Oeser H. Biopharmaceutical characterization of sotalol-containing oral immediate release drug products. Eur J Pharm Biopharm 2004; 58: 145-150.
5. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. Molecular properties of WHO essential drugs and provisional biopharmaceutics classification. Mol Pharm 2004; 1: 85-96.
6. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58: 265-278.
7. Panchagnula R, Agrawal S, Ashokraj Y, Varma MVS, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, Blomberg B, Fourie B, Roscignio G, Wire R, Laing R, Evans P, Moore T. Fixed dose combination for tuberculosis: Lessons learned from a clinical, formulation and regulatory perspective. Background document for meeting on fixed dose combinations for HIV/AIDS, Tuberculosis and malaria. Current status and future challenges from clinical, regulatory, intellectual property and production perspectives. WHO, 15-17th, Dec 2003; Geneva.
8. Agarwal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm 2004; 287: 97-112.
9. Available from. http://www.cerep.fr/cerep/users/pages/downloads/ Documents/Marketing/Pharmacology%20&%20ADME/Application%20notes/ Caco-2permeability.pdf (Accessed on 07-12-2005).
10. Collett A, Tanianis-Hughes J, Warhurst G. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem Pharmacol 2004; 68: 783-790.
11. Mohan B, Sharda N, Singh S. Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin. J Pharm Biomed Anal 2003; 31: 607-612.
12. United States Pharamcopeia, 26th rev, Asian Edition, United States Pharmacopeial Convention, Inc, Rockville, MD, 2003.
13. Hohnjec M, Kuftinec J. Ranitidine hydrochloride. In: Florey K, ed. Analytical profiles of drug substances. Academic Press: Florida, 1986:533-561.
14. Guidance for industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. August 2000, CDER/FDA. (http://www.fda.gov/cder/guidance/3618fnl.htm).
15. Mariappan TT, Singh S. Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted sac techniques. Mol Pharm 2004; 1: 363-367.
16. Petri WA. Antimicrobial agents. In: Hardman J. G., Limbird L. E., eds. Goodman and Gilman The pharmacological basis of Therapeutics, The McGraw-Hill Companies, Inc: Washington, 2001:1273-1295.
17. Mariappan TT, Singh S. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. Int J Tuberc Lung Dis 2003; 7: 897-903.
18. Koup JR. Pharmacokinetics of rifampicin in children. II: Oral bioavailability. Ther Drug Monit 1986; 8: 17-22.
19. Loos U, Musch E, Jensen JC, Schwabe HK, Eichelbaum M. Influence of the enzyme induction by rifampicin on its presystemic metabolism. Pharmac Ther 1987; 33: 201-204.
20. Sweeny RW, Divers TJ, Bensen C. Pharmacokinetics of rifampicin in calves and adult sheep. J Vet Pharmacol Ther 1988; 11: 413-416.
21. Kohn CW, Sams R, Kowalske JJ. Pharmacokinetics of single intravenous and single and multiple oral administration of rifampicin in mares. J Vet Pharmacol Ther 1993; 16: 119-131.
22. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticles-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003; 52: 981-986.
23. Mariappan TT, Singh S, Pandey R, Khuller GK. Influence of the mode of intravenous administration and the time of sampling on absolute bioavailability of rifampicin. Clin Res Regul Aff 2005; 22: 119-128.
24. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm 2001; 228: 53-67.
25. Singh S, Mariappan TT, Sharda N, Singh B. Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions. Pharm Pharmacol Commun 2000; 6: 491-494.
26. Holdiness MR. Clinical pharmacokinetics of the anti tubercular drugs. Clin Pharmacokinet 1984; 9: 511-544.
27. Takada K, Mikami H, Asada S, Taisuo K, Muranishi S. Biopharmaceutical study of the hepatobiliary transport of drugs. VII. Improvement of the bioavailability of rifampicin by dosage form design. Chem Pharm Bull 1978; 26: 19-24.
28. Zutshi RK, Singh R, Zutshi U, Johri RK, Atal CK. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. J Assoc Physicians India 1985; 33: 223-224.
29. Prakash J, Velpandian T, Pande JN, Gupta SK. Serum rifampicin levels in patients with tuberculosis: Effects of p-glycoprotein and CYP3A4 blockers on its absorption. Clin Drug Invest 2003; 23: 463-472.
30. Furesz S, Scotti R, Pallanza R, Mapelli E. Rifampicin: A new rifamycin III. Absorption, distribution, and elimination in man. Arznemittel-Forsch 1967; 17: 534-537.
31. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharm Tox Meth 2000; 44: 235-249.
32. Dowty ME, Dietsch CR. Improved prediction of in vivo peroral absorption from in vitro intestinal permeability using an internal standard to control for intra- and inter-rat variability. Pharm Res 1997; 12: 1792-1797.
33. Takamatshu N, Kim ON, Welage LS, Idkaidek NM, Hayashi Y, Barnett J, Yamamoto R, Lipka E, Lennernas H, Hussain A, Lesko L, Amidon GL. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm Res 2001; 18: 742-744.
34. Washington N, Lamont G, Wilson CG, Washington C, Withington R. The effect of high and low fat meals on the absorption of rifampicin from the gastrointestinal tract in volunteer subjects. Int J Pharm 1994; 108: 125-131.